Ceftriaxone therapy for serious bacterial infections

D. S. Lockman, R. C. Trincher, J. P. Rissing

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Ceftriaxone is a new semisynthetic cephalosporin with a very long serum half-life and broad coverage against Enterobacteriaceae and Pseudomonas aeruginosa. Clinical and microbiological efficacies were evaluated in 51 infections occurring in 46 patients: 20 pneumonias, 19 urinary tract infections, seven soft-tissue infections, two septic arthritis infections, two primary bacteremias and one otitis media. The usual dose of ceftriaxone was one gram every 12 hours. Improvement of cure occurred in 92% of infections; microbiological cure occurred in 93% of infections. A mild rise in liver function tests occurred in 14% of the 51 infections but was not thought clinically significant.

Original languageEnglish (US)
Pages (from-to)574-581
Number of pages8
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume36
Issue number3
StatePublished - Dec 1 1984

Fingerprint

Ceftriaxone
Bacterial Infections
Infection
Therapeutics
Infectious Arthritis
Soft Tissue Infections
Liver Function Tests
Otitis Media
Enterobacteriaceae
Cephalosporins
Bacteremia
Urinary Tract Infections
Pseudomonas aeruginosa
Half-Life
Pneumonia
Serum

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Ceftriaxone therapy for serious bacterial infections. / Lockman, D. S.; Trincher, R. C.; Rissing, J. P.

In: Current Therapeutic Research - Clinical and Experimental, Vol. 36, No. 3, 01.12.1984, p. 574-581.

Research output: Contribution to journalArticle

@article{1965755ceb8a4625b409584cdb39fd18,
title = "Ceftriaxone therapy for serious bacterial infections",
abstract = "Ceftriaxone is a new semisynthetic cephalosporin with a very long serum half-life and broad coverage against Enterobacteriaceae and Pseudomonas aeruginosa. Clinical and microbiological efficacies were evaluated in 51 infections occurring in 46 patients: 20 pneumonias, 19 urinary tract infections, seven soft-tissue infections, two septic arthritis infections, two primary bacteremias and one otitis media. The usual dose of ceftriaxone was one gram every 12 hours. Improvement of cure occurred in 92{\%} of infections; microbiological cure occurred in 93{\%} of infections. A mild rise in liver function tests occurred in 14{\%} of the 51 infections but was not thought clinically significant.",
author = "Lockman, {D. S.} and Trincher, {R. C.} and Rissing, {J. P.}",
year = "1984",
month = "12",
day = "1",
language = "English (US)",
volume = "36",
pages = "574--581",
journal = "Current Therapeutic Research",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "3",

}

TY - JOUR

T1 - Ceftriaxone therapy for serious bacterial infections

AU - Lockman, D. S.

AU - Trincher, R. C.

AU - Rissing, J. P.

PY - 1984/12/1

Y1 - 1984/12/1

N2 - Ceftriaxone is a new semisynthetic cephalosporin with a very long serum half-life and broad coverage against Enterobacteriaceae and Pseudomonas aeruginosa. Clinical and microbiological efficacies were evaluated in 51 infections occurring in 46 patients: 20 pneumonias, 19 urinary tract infections, seven soft-tissue infections, two septic arthritis infections, two primary bacteremias and one otitis media. The usual dose of ceftriaxone was one gram every 12 hours. Improvement of cure occurred in 92% of infections; microbiological cure occurred in 93% of infections. A mild rise in liver function tests occurred in 14% of the 51 infections but was not thought clinically significant.

AB - Ceftriaxone is a new semisynthetic cephalosporin with a very long serum half-life and broad coverage against Enterobacteriaceae and Pseudomonas aeruginosa. Clinical and microbiological efficacies were evaluated in 51 infections occurring in 46 patients: 20 pneumonias, 19 urinary tract infections, seven soft-tissue infections, two septic arthritis infections, two primary bacteremias and one otitis media. The usual dose of ceftriaxone was one gram every 12 hours. Improvement of cure occurred in 92% of infections; microbiological cure occurred in 93% of infections. A mild rise in liver function tests occurred in 14% of the 51 infections but was not thought clinically significant.

UR - http://www.scopus.com/inward/record.url?scp=0021673092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021673092&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 574

EP - 581

JO - Current Therapeutic Research

JF - Current Therapeutic Research

SN - 0011-393X

IS - 3

ER -